Tag - SYRS


Brookline starts Syros Pharma at buy; PT $19

Brookline Capital Markets launched coverage of Syros Pharmaceuticals (NASDAQ:SYRS) with a “buy” rating and a 12-to-18-month price target of $19.00. The stock closed at $8.89 on Nov. 9. Syros is developing gene-control...


HCW ups Syros to buy; PT to $15 from $11

H.C. Wainwright upgraded Syros Pharmaceuticals (NASDAQ:SYRS) to “buy” from “neutral” and upped its price target to $15 from $11, saying the company “has turned a corner, in our opinion.” The stock closed at $6.67 on Nov...